These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

339 related items for PubMed ID: 8558517

  • 1. Design, synthesis, and structure-activity relationship studies of novel 1-[(1-acyl-4-piperidyl)methyl]-1H-2- methylimidazo[4,5-c]pyridine derivatives as potent, orally active platelet-activating factor antagonists.
    Carceller E, Merlos M, Giral M, Balsa D, García-Rafanell J, Forn J.
    J Med Chem; 1996 Jan 19; 39(2):487-93. PubMed ID: 8558517
    [Abstract] [Full Text] [Related]

  • 2. Discovery and evaluation of a series of 3-acylindole imidazopyridine platelet-activating factor antagonists.
    Curtin ML, Davidsen SK, Heyman HR, Garland RB, Sheppard GS, Florjancic AS, Xu L, Carrera GM, Steinman DH, Trautmann JA, Albert DH, Magoc TJ, Tapang P, Rhein DA, Conway RG, Luo G, Denissen JF, Marsh KC, Morgan DW, Summers JB.
    J Med Chem; 1998 Jan 01; 41(1):74-95. PubMed ID: 9438024
    [Abstract] [Full Text] [Related]

  • 3. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF).
    Merlos M, Giral M, Balsa D, Ferrando R, Queralt M, Puigdemont A, García-Rafanell J, Forn J.
    J Pharmacol Exp Ther; 1997 Jan 01; 280(1):114-21. PubMed ID: 8996188
    [Abstract] [Full Text] [Related]

  • 4. Synthesis and structure-activity relationships of 1-acyl-4-((2-methyl-3-pyridyl)cyanomethyl)piperazines as PAF antagonists.
    Carceller E, Merlos M, Giral M, Almansa C, Bartrolí J, García-Rafanell J, Forn J.
    J Med Chem; 1993 Oct 01; 36(20):2984-97. PubMed ID: 8411016
    [Abstract] [Full Text] [Related]

  • 5. Novel antagonists of platelet-activating factor. 2. Synthesis and structure-activity relationships of potent and long-acting heterofused [1,5]benzodiazepine and [1,4]diazepine derivatives of 2-methyl-1-phenylimidazo[4,5-c]pyridine.
    Fray MJ, Bull DJ, Cooper K, Parry MJ, Stefaniak MH.
    J Med Chem; 1995 Sep 01; 38(18):3524-35. PubMed ID: 7658439
    [Abstract] [Full Text] [Related]

  • 6. 1,4-Dihydropyridines as antagonists of platelet activating factor. 1. Synthesis and structure-activity relationships of 2-(4-heterocyclyl)phenyl derivatives.
    Cooper K, Fray MJ, Parry MJ, Richardson K, Steele J.
    J Med Chem; 1992 Aug 21; 35(17):3115-29. PubMed ID: 1507200
    [Abstract] [Full Text] [Related]

  • 7. [(3-Pyridylalkyl)piperidylidene]benzocycloheptapyridine derivatives as dual antagonists of PAF and histamine.
    Carceller E, Merlos M, Giral M, Balsa D, Almansa C, Bartrolí J, García-Rafanell J, Forn J.
    J Med Chem; 1994 Aug 19; 37(17):2697-703. PubMed ID: 7914928
    [Abstract] [Full Text] [Related]

  • 8. Novel azo derivatives as prodrugs of 5-aminosalicylic acid and amino derivatives with potent platelet activating factor antagonist activity.
    Carceller E, Salas J, Merlos M, Giral M, Ferrando R, Escamilla I, Ramis J, García-Rafanell J, Forn J.
    J Med Chem; 2001 Aug 30; 44(18):3001-13. PubMed ID: 11520209
    [Abstract] [Full Text] [Related]

  • 9. Non-peptide glycoprotein IIb/IIIa antagonists. 11. Design and in vivo evaluation of 3,4-dihydro-1 (1H)-isoquinolinone-based antagonists and ethyl ester prodrugs.
    Hutchinson JH, Cook JJ, Brashear KM, Breslin MJ, Glass JD, Gould RJ, Halczenko W, Holahan MA, Lynch RJ, Sitko GR, Stranieri MT, Hartman GD.
    J Med Chem; 1996 Nov 08; 39(23):4583-91. PubMed ID: 8917647
    [Abstract] [Full Text] [Related]

  • 10. Novel antagonists of platelet-activating factor. 1. Synthesis and structure-activity relationships of benzodiazepine and benzazepine derivatives of 2-methyl-1-phenylimidazo[4,5-c]pyridine.
    Fray MJ, Cooper K, Parry MJ, Richardson K, Steele J.
    J Med Chem; 1995 Sep 01; 38(18):3514-23. PubMed ID: 7658438
    [Abstract] [Full Text] [Related]

  • 11. Structure-activity relationships in platelet-activating factor (PAF antagonists). 6. Synthesis and in vitro antagonistic activities of 2-substituted 5-oxotetrahydrofurans.
    Favre E, Heymans F, Redeuilh C, Batt JP, Massicot F, Blavet N, Braquet P, Godfroid JJ.
    J Lipid Mediat; 1992 Feb 01; 5(1):23-40. PubMed ID: 1449553
    [Abstract] [Full Text] [Related]

  • 12. UK-74,505, a novel and selective PAF antagonist, exhibits potent and long lasting activity in vivo.
    Alabaster VA, Keir RF, Parry MJ, de Souza RN.
    Agents Actions Suppl; 1991 Feb 01; 34():221-7. PubMed ID: 1793066
    [Abstract] [Full Text] [Related]

  • 13. Thromboxane modulating agents. 3. 1H-imidazol-1-ylalkyl- and 3-pyridinylalkyl-substituted 3-[2-[(arylsulfonyl)amino]ethyl]benzenepropanoic acid derivatives as dual thromboxane synthase inhibitor/thromboxane receptor antagonists.
    Dickinson RP, Dack KN, Long CJ, Steele J.
    J Med Chem; 1997 Oct 10; 40(21):3442-52. PubMed ID: 9341919
    [Abstract] [Full Text] [Related]

  • 14. Effects of a new platelet-activating factor antagonist, UR-12670, on several endotoxic shock markers in rats.
    Balsa D, Merlos M, Giral M, Ferrando R, Garcia-Rafanell J, Forn J.
    Drugs Exp Clin Res; 1997 Oct 10; 23(5-6):191-9. PubMed ID: 9515229
    [Abstract] [Full Text] [Related]

  • 15. Pharmacological profile of UK-74,505, a novel and selective PAF antagonist with potent and prolonged oral activity.
    Parry MJ, Alabaster VA, Cheeseman HE, Cooper K, deSouza RN, Keir RF.
    J Lipid Mediat Cell Signal; 1994 Sep 10; 10(3):251-68. PubMed ID: 7812676
    [Abstract] [Full Text] [Related]

  • 16. Biological effect of orally active platelet-activating factor receptor antagonist SM-10661.
    Komuro Y, Imanishi N, Uchida M, Morooka S.
    Mol Pharmacol; 1990 Sep 10; 38(3):378-84. PubMed ID: 2402227
    [Abstract] [Full Text] [Related]

  • 17. Biological effects of the new platelet-activating factor receptor antagonist (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride.
    Imanishi N, Murakami-Uchida M, Koike H, Natsume Y, Morooka S.
    Arzneimittelforschung; 1994 Mar 10; 44(3):317-22. PubMed ID: 8192697
    [Abstract] [Full Text] [Related]

  • 18. Structure-activity relationships in platelet-activating factor. 12. Synthesis and biological evaluation of platelet-activating factor antagonists with anti-HIV-1 activity.
    Serradji N, Martin M, Bensaid O, Cisternino S, Rousselle C, Dereuddre-Bosquet N, Huet J, Redeuilh C, Lamouri A, Dong CZ, Clayette P, Scherrmann JM, Dormont D, Heymans F.
    J Med Chem; 2004 Dec 02; 47(25):6410-9. PubMed ID: 15566310
    [Abstract] [Full Text] [Related]

  • 19. [PAF-antagonists with phospholipid structure. 4. Alkylcarbamoylphospholipids with heteroarene and heterocyclase head groups and variation of the P-N-distance; synthesis, characterization and structure-activity relationship].
    Kertscher HP, Schmidt B, Ostermann G.
    Pharmazie; 1992 Mar 02; 47(3):172-4. PubMed ID: 1615020
    [Abstract] [Full Text] [Related]

  • 20. Guanidine derivatives as combined thromboxane A2 receptor antagonists and synthase inhibitors.
    Soyka R, Guth BD, Weisenberger HM, Luger P, Müller TH.
    J Med Chem; 1999 Apr 08; 42(7):1235-49. PubMed ID: 10197967
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.